Trials / Completed
CompletedNCT01061970
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy
Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- QuatRx Pharmaceuticals Company · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 4 weeks in the treatment of hypogonadal men with chronic obstructive pulmonary disease (COPD) that are on oral glucocorticoid therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fispemifene | once daily for 4 weeks |
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-10-01
- First posted
- 2010-02-03
- Last updated
- 2010-02-03
Source: ClinicalTrials.gov record NCT01061970. Inclusion in this directory is not an endorsement.